Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

VentriPoint Diagnostics Ltd. (VPTDF) Business Model Designed For Rich Recurring Revenue

|Includes: VentriPoint Diagnostics Ltd. (VPTDF)

The VentriPoint business model parallels that of GE Healthcare, Phillips, Siemens, and Toshiba, with initial technology-based product sales acting as a platform for a range of recurring revenues. VentriPoint's innovative ultrasound based medical imaging analysis technology provides an easy-to-use and highly cost-effective alternative to MRI and other high-end medical diagnostic tools and procedures. It's of special value for right heart analysis, where a standard ultrasound approach is ineffective, and for pediatric patients where elaborate MRI scanning may be difficult to tolerate. It's a technology of widening application, designed to save both time and money, and it's finding a home in a growing number of hospitals around the world.

The system's capital purchase list price of $100,000 per unit sets up a base for the following recurring revenues:

•$10,000 per year per unit - Access to databases, software, and hardware maintenance

•$20,000 - $50,000 per year per unit - Software upgrades, access to new databases and additional training

•$5,000 - $10,000 per year per unit - Training services and certification, with recertification required if you have not used the software for 3 months

For smaller clinics, and as applications increase, the move will be to a per-use revenue model.

Sales projections for year-end 2013 total $3 to $5 million, including recurring revenue from earlier installations, for new applications, support, maintenance, and training, with projections for 2014 totaling $10 to $15 million.

The company targets a large market opportunity, representing a well described unmet clinical need, with gross margins of 80%. The technology is patented and proprietary, with excellent clinical validation by respected experts. It already holds Canadian and European regulatory approvals, with FDA processing underway.

For more information on VentriPoint's leading-edge cardiac diagnostic technology, visit

Please see disclaimer on the QualityStocks website: